https://orcid.org/0000-0003-1284-9776
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Background: Five EGFR-tyrosine kinase inhibitors (EGFR TKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy of EGFR TKIs in the Japanese population. Materials & methods: A systematic review identified randomized controlled trials examining the efficacy of first-line EGFR TKIs. A Bayesian network meta-analysis was used to assess these EGFR TKI comparisons for progression-free survival (PFS). Results: A total of seven randomized controlled trials were identified and considered for network meta-analysis. Dacomitinib showed a trend toward improved PFS versus all comparators. Conclusion: Dacomitinib demonstrated a trend toward improved PFS and therefore, should be considered one of the standard first-line therapies for Japanese patients diagnosed with EGFR+ non-small-cell lung cancer.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2020-0651
Acknowledgments
The authorswould like to thank E Graves from Medlior for her support with the medical writing and editorial review.
Financial & competing interestsdisclosures
This work was sponsored by Pfizer Inc., NY, USA. MS Farris is employed and KA Larkin-Kaiser and T Scory were formerly employed by Medlior Health Outcomes Research Ltd, who were paid consultants to Pfizer in connection with the study design of the project and the development of this manuscript. JI Ivanova, KD Wilner, K Matsumura and H Kikkawa are employed by Pfizer and own stock. K Nakagawa has received payments for serving as an advisor to Astellas Pharma Inc., Eli Lilly Japan KK, Ono and Takeda. He has also received honoraria from Astellas Pharma Inc., AstraZeneca KK, AYUMI Pharmaceutical Corporation, Bristol-Myers Squibb, CareNet, Inc., Chugai Pharmaceutical, Clinical Trial Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan KK, Hisamitsu Pharmaceutical Co., Inc., KYORIN Pharmaceutical Co., Ltd., Medical Review Co., Ltd., MEDICUS SHUPPAN, Publishers Co., Ltd., MSD KK, NANZANDO Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Nikkei Business Publications, Inc., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma KK, Ono, Pfizer Japan Inc., Reno Medical KK/SymBio Pharmaceuticals Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Thermo Fisher Scientific KK, YODOSHA Co., Ltd. and YOMIURI TELECASTING CORPORATION, and research funding from A2 Healthcare Corp., AbbVie, Astellas Pharma, AstraZeneca KK, Bayer Yakuhin, Ltd., Bristol-Myers Squibb, Chugai, CMIC Shift Zero KK, Covance Inc., Daiichi Sankyo, Eisai, Eli Lilly Japan KK, EP-CRSU Co., Ltd., EPS Corporation, EPS International Co., Ltd., GlaxoSmithKline KK, Gritstone Oncology, ICON Japan KK, inVentiv Health Japan, IQVIA Services JAPAN KK, Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin, Linical Co., Ltd., Merck Serono, MSD KK, Nippon Boehringer Ingelheim, Novartis Pharma KK, Ono, Otsuka Pharmaceutical Co., Ltd., PAREXEL International, Pfizer Japan, Quintiles Inc., SymBio Pharmaceuticals Ltd., Taiho, Takeda, and Yakult Honsha Co., Ltd. Medlior was responsible for collection, analysis and reporting of data, for which it received funding from Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
E Graves from Medlior provided support with the medical writing and editorial review, which was funded by Pfizer.